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African American men have among the highest prostate cancer incidence rates in the world yet rates among their African
counterparts are unclear. In this paper, we compared reported rates among black men of Sub-Saharan African descent using data
from the International Agency for Research on Cancer (IARC) and the National Cancer Institute Surveillance, Epidemiology, and
End Results Program for 1973–2007. Although population-based data in Africa are quite limited, the available data from IARC
showed that rates among blacks were highest in the East (10.7–38.1 per 100,000 man-years, age-adjusted world standard) and
lowest in the West (4.7–19.8). These rates were considerably lower than those of 80.0–195.3 observed among African Americans.
Rates in Africa increased over time (1987–2002) and have been comparable to those for distant stage in African Americans. These
patterns are likely due to diﬀerences between African and African American men in medical care access, screening, registry quality,
geneticdiversity,andWesternization.IncidenceratesinAfricawilllikelycontinuetorisewithimprovingeconomiesandincreasing
Westernization, warranting the need for more high-quality population-based registration to monitor cancer incidence in Africa.
1.Introduction
African American men have among the highest reported
prostate cancer rates in the world [1, 2]. However, whether
similarly high rates occur among men in Africa is unclear
[3]. Previous reports from Africa were mostly limited to case
series and hospital-based data, largely due to the diﬃculty in
establishing high-quality population-based cancer registries
in Africa [3–6]. Because West Africans and African Ameri-
cans share a common genetic ancestry yet have very diﬀerent
lifestyles, a better understanding of prostate cancer rates and
patterns among Sub-Saharan Africans may provide unique
insights into the etiology of this disease [7]. Therefore, we
examined available 1973–2007 incidence rates from Sub-
Saharan Africa and the United States (US).
2.MaterialsandMethods
We used prostate cancer incidence data for Africa from
publications of the International Agency for Research on
Cancer (IARC; http://www-dep.iarc.fr/): (1) Cancer Inci-
dence in Five Continents (CI5), volumes IV-IX [4, 8]a n d
(2) Cancer in Africa: Epidemiology and Prevention [3]. We
included only registries that reported at least 10 cases of
prostate cancer that were diagnosed during each time period
and from countries that had populations that were more
than 95% Black African or reported rates speciﬁc to Blacks.
Twelve African registries ﬁt these criteria (see Table 1); none
of the registries in North or Central Africa met the inclusion
criteria.Ofthe12registriesselected,nineregistriesarepopu-
lation based with data collected at the national (The Gambia
andSwaziland)orregional(Conakry,Guinea;Bamako,Mali;
Niamey, Niger; Ibadan, Nigeria; Eldoret, Kenya; Blantyre,
Malawi; Kyadondo, Uganda; Harare, Zimbabwe: African)
levels. Of the other three registries, Blantyre, Malawi did not
have cancer information based on death certiﬁcates due to
absence of death registration in the country, South Africa is
primarilypathology-based,andNamibiaisprimarilypathol-
ogy based with some cases registered from the oncology
services in its capital and largest city of Windhoek; it was not2 Prostate Cancer
reported whether South Africa or Namibia included cancer
information from death certiﬁcates.
For comparison with these African data, we calculated
rates for US Blacks and Whites from the National Cancer
Institute (NCI) Surveillance, Epidemiology, and End Results
(SEER) Program for the original nine registries combined
using SEER∗Stat version 7.0.4 (http://www.seer.cancer.gov/
seerstat; NCI, Bethesda, Md) for total prostate cancer [10].
Although SEER expanded to include 13 registries in 1992
and further to 17 registries in 2000, to maintain geographic
homogeneity over time, we restricted our analysis to the
original 9 registries throughout. SEER annually provides
updated rates, which for the earlier years are very similar to
thosereportedinCI5(datanotshown).SEERincludesstage-
speciﬁc data, which are not reported in CI5. Classiﬁcation
of the prostate cancer stage at diagnosis has not been
consistentoverthe35-yearperiodoftheSEERprogram,with
diﬃculties becoming apparent in delineating localized versus
regional stage and more recently localized versus unknown
stage. It appeared, however, that the deﬁnition and determi-
nationofdistant-stagediseasewasmoreconsistentovertime,
so we calculated rates according to SEER historical stage
distant versus nondistant, including localized/regional and
stage unknown [10]. The SEER November 2004 submission
dataﬁlewasusedtocalculatethestage-speciﬁcratesforcases
diagnosed during 1973–1987 [11] and the November 2009
data ﬁle for cases diagnosed during 1988–2007 [10]. Cases
that are distant stage at diagnosis in the US are likely to be
clinically apparent and perhaps more comparable to most
cases diagnosed in Africa. All rates were directly age adjusted
to Segi’s world standard population [9] and expressed per
100,000 man-years. 95% conﬁdence intervals (CI) extracted
from CI5, were estimated for data from Cancer in Africa (see
table footnote for method), or provided by SEER∗Stat.
We examined trends for SEER during 1973–2007 and
for three African registries that reported rates for at least
three time points during that time period. We used log scales
to plot the rates such that a slope of 10 degrees portrayed
a change of 1% per year (Origin version 8.0; OriginLab
Corporation, Northampton, Ma, USA) [12].
3. Results andDiscussion
Among the African countries, the number of cases ranged
from 20 in The Gambia (1997-1998) to 3,432 in South
African Blacks (1989–1992) (Table 1). Incidence varied sub-
stantially by region, with rates highest in the East (10.7–
38.1 per 100,000 man-years), intermediate in the South
(14.3–21.8), and lowest in the West (4.7–19.8). The reported
rate for Harare, Zimbabwe (38.1 during 1998–2002) was
8 times the rate in The Gambia (4.7 during 1997-1998).
In comparison, rates among US Blacks were considerably
higher up to 40 times those in Africa: 195.3 in US Blacks
during 1993–1997 versus 4.7 in The Gambia during 1997-
1998.
Reasons for the large variation of prostate cancer in
blacks within the African continent and the observed
East-West disparity are unclear but are likely related to
diﬀerences in medical care access, registry quality, including
completeness of case ascertainment and estimates of popula-
tions at risk, screening practices, as well as lifestyle factors in
subpopulations [4]. For most of Africa, medical care access
is limited, with only 4% of Ghanaian men in 2004–2006,
for instance, having health insurance (unpublished data);
in contrast, about 80% of non-Hispanic blacks in the U.S.
had some type of health insurance coverage in 2008 [13].
In the more developed country of South Africa, diagnostic
and screening facilities may be more accessible to the general
population, but the racial disparity seen in prostate cancer
incidence between blacks and whites [7] suggest that blacks
may still have poorer access to medical care. Postapartheid,
access to medical aid for whites were about seven times that
of blacks [14]. Underdiagnosis of prostate cancer is likely in
populations with limited health care access [3, 7].
Quality of the medical care systems and registries also
may have a substantial impact on the completeness and
accuracy of the reported incidence rates. Availability of
pathology services (reﬂected by percent of cases microscop-
ically veriﬁed; Table 1) likely compromises the quality of
cancerdiagnosis.Forexample,inTheGambia,whichhadthe
lowest prostate cancer incidence rate, only 20% of cases were
morphologically veriﬁed during 1997-1998 [4]. In contrast,
in Harare, Zimbabwe, which had the highest incidence
rate, 63% of cases had morphological veriﬁcation during
1998–2002 [8]. Both countries had much lower pathological
conﬁrmation rates of cancer than the US, where more than
93% of cases have been histologically conﬁrmed since 1973
[10]. On the other hand, a high conﬁrmation rate, such
as in Namibia (97%) and South African Blacks (100%),
suggests that the registry relied primarily on pathology
records and that nonconﬁrmed cases were not included. A
high proportion of cases that were ascertained based on
death certiﬁcates only suggests that case ﬁnding has failed to
identify cases that have not died, again potentially resulting
in rate underestimation. This may occur in populations
with limited infrastructure to support comprehensive data
collection [3, 15], especially when diseases like cancer are
less of a priority [16, 17]. Thus, the true prostate cancer
incidence in African men is likely higher than what is
reported here. There also may be uncertainties in the
accuracy of the population enumerations and estimates of
person-yearsatrisk[4,8],whichcouldresultineitherunder-
or overestimation of the rates.
Unlike the US where increasing and widespread use of
prostate-speciﬁc antigen (PSA) screening contributed to the
rapid rise in incidence during the early 1990s [18], the
risingSub-SaharanAfricanratesweresimilartotheincreases
seen for total rates in the US before PSA screening was
implemented (Figure 1). PSA screening is still uncommon in
most parts of Sub-Saharan Africa, with reported prevalence
of 2.5% in Ghana (unpublished data) and 4% in Senegal
[19]. Within the SEER data, rates were consistently higher
among blacks than whites, rose through the 1990s, especially
rapidly during 1980s–1990s overall and for nondistant
disease stage before leveling oﬀ during the 2000s, and
declined notably for distant stage since 1990. Notably, while
the total prostate cancer rates in the US were consistently
much higher than those in Africa, total rates in East AfricaProstate Cancer 3
Table 1: Age-adjusted prostate cancer incidence ratesa per 100,000 man-years, 95% conﬁdence intervals (CIs), percent microscopically
veriﬁed, and percent reported by death certiﬁcate only in Sub-Saharan Africa and the United States, 1973–2007.
Location and/or race Source Time
period No. cases Incidence
ratea 95% CIb Microscopically
veriﬁed (%)
Death certiﬁcate
only (%)
East Africa
Blantyre, Malawi Cancer in Africa 2000-2001 30 10.7 6.9–14.5 47 NK
Eldoret, Kenya Cancer in Africa 1998–2000 54 16.8 12.3–21.3 30 NK
Harare, Zimbabwe: African CI5 VII 1990–1992 112 28.3 22.5–43.1 64 9
CI5 VIII 1993–1997 251 30.7 26.5–34.9 56 15
CI5 IX 1998–2002 418 38.1 34.1–42.1 63 15
Kyadondo, Uganda
CI5 VII 1991–1993 86 27.7 21.6–33.8 67 NK
CI5 VIII 1993–1997 215 37.1 31.7–42.5 77 0
CI5 IX 1998–2002 262 37.6 32.8–42.4 58 NK
Southern Africa
Namibia Cancer in Africa 1995–1998 352 21.8 19.5–24.1 97 NK
South Africa: blacks Cancer in Africa 1989–1992 3432 14.3 13.8–14.8 100 NK
Swaziland Cancer in Africa 1996–1999 153 21.5 18.1–24.9 24 NK
West Africa
Bamako, Mali CI5 VI 1987–1989 21 6.3 3.5–9.1 5 5
CI5 VII 1988–1992 33 5.2 3.4–7.0 21 6
CI5 VIII 1994–1996 29 7.6 4.8–10.4 55 3
Conakry, Guinea Cancer in Africa 1996–1999 62 9.7 7.3–12.1 45 NK
Ibadan, Nigeria Cancer in Africa 1998–1999 115 19.8 16.2–23.4 70 NK
Niamey, Niger Cancer in Africa 1993–1999 41 10.8 7.5–14.1 34 NK
The Gambia CI5 VIII 1997-1998 20 4.7 2.5–6.9 20 NK
North America
United States
Blacks NCI-SEER 1973–1977 2666 80 77.0–83.1 93 1
NCI-SEER 1978–1982 3783 89.8 86.8–92.6 95 1
NCI-SEER 1983–1987 4754 100.0 97.1–102.8 96 1
NCI-SEER 1988–1992 7511 143.3 140.1–146.6 97 0
NCI-SEER 1993–1997 10853 195.9 191.6–199.1 96 1
NCI-SEER 1998–2002 11940 192.9 186.6–193.7 97 1
NCI-SEER 2003–2007 12618 172.8 169.8–176.0 98 1
Whites NCI-SEER 1973–1977 24212 47.9 47.3–48.5 94 1
NCI-SEER 1978–1982 31389 54.8 54.1–55.3 95 1
NCI-SEER 1983–1987 39492 63.5 62.8–64.0 97 0
NCI-SEER 1988–1992 68863 104.3 103.3–104.9 96 1
NCI-SEER 1993–1997 73687 111.8 110.5–112.2 97 1
NCI-SEER 1998–2002 80100 116.9 115.1–116.8 97 1
NCI-SEER 2003–2007 80022 107.0 106.2–107.8 98 1
CI: conﬁdence interval; NK: not known; CI5: Cancer Incidence in Five Continents; NCI-SEER: National Cancer Institute’s Surveillance, Epidemiology, and
End Results Program: nine registries.
aAll rates are age adjusted to Segi’s world standard population [9]; African rates are shown only for populations at least 95% black or are speciﬁc for black
Africans.
b95% CIs were obtained directly from CI5, were estimated for data from the Cancer in Africa publication by multiplying the standard error (incidence rate
divided by the square root of the total number of cases) by 1.96, and adding to and subtracting from the incidence rate to obtain the upper and lower bounds,
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Figure 1:Age-adjusted(Segi’sworldstandard)prostatecancerincidenceinSub-SaharanAfricaandtheUnitedStates,1973–2007.(a)Africa:
total prostate cancer rates from registries in three African cities; the populations of both Mali and Uganda were >95% black, and the rates
for Zimbabwe were speciﬁc for black Africans. US: SEER nine registries combined for blacks (b) and whites (c): total and by SEER historical
stage: nondistant and distant. All rates are for 3–5 year time periods (see Table 1).
(Uganda and Zimbabwe) were similar to the distant-stage
rate among black Americans during the 1980s. Total rates
in East Africa have also been higher than distant-stage rates
reported for black and white Americans in recent years. This
observation is also consistent with the fact that screening
is uncommon in Africa, and thus cancers are more likely
diagnosedatamoreadvancedstage.Infact,advanceddisease
accountedfor75%ofcasesinGhana (unpublisheddata)and
47.9% in Senegal [20].
Similar to reasons given above for the geographic varia-
tion in rates within Africa, it is likely that improved health
care systems and better ascertainment and reporting of cases
may contribute to the rising rates in Africa [7, 21]. However,
it is also possible that increased westernization in Africa in
recent years, including changes in diet and lifestyle, may also
play a role. For example, recent population-based data from
Ghana show that the prevalence of obesity, a potential eﬀect
of Westernization, increased from 5% in 1998 [22]t o9 %i n
2004–2006, and the prevalence of overweight increased from
17% to 32% (unpublished data). US non-Hispanic Black
men had a prevalence of obesity and overweight of 34.0%
and 69.1%, respectively, in 2003-2004 [23]. Both clinical and
etiologic investigations in African men are needed to further
clarify reasons for the rising prostate cancer incidence in
Africa.
Considering that the level of Westernization in Africa is
still much lower than that in the US, the observation that
total incidence rates in East Africa (Zimbabwe and Uganda),
even in the earlier time period, were slightly higher than
those of distant stage disease among African Americans is
consistent with recent ﬁndings from genome-wide associa-
tion studies (GWAS) showing that genetics are an important
factor in prostate cancer. Recent GWAS have linked over 30
independent genetic loci to higher risks of prostate cancer
in populations of European descent, including multiple loci
in chromosome 8q24 [24–35]. Notably, some of the known
risk alleles in 8q24 are more common in African Amer-
icans than non-African populations [28], suggesting that
geneticvariationmaycontributetoracialdisparitiesbetween
African American and other populations. In a large study of
GWAS-identiﬁed risk variants and prostate cancer in African
Americans, signiﬁcant associations were found for some of
the GWAS-identiﬁed risk variants in the same direction and
of similar magnitude as those reported in men of European
descent [36]. Most notably, all reported risk loci at 8q24 were
signiﬁcantlyassociatedwithprostatecancerwith8q24region
2 attaining genome-wide signiﬁcance levels. A recent GWAS
speciﬁc to men of African descent also found similar results
for previously identiﬁed variants in 8q24 but discovered an
additional susceptibility locus at 17q21 [37]. It is noteworthy
that the frequency of the 17q21 risk variation (rs7210100)
is 4 to 7% in men of African ancestry, including Ghanaian
men (7%), but is less than 1% in non-African populations
(based on data from the 1000 Genomes Project). This novel
ﬁndingsuggeststhatsomerisklocimaybespeciﬁctoAfrican
populations. Whether 8q24, 17q21, or other risk variantsProstate Cancer 5
play an important role in prostate cancer in African men
warrants further conﬁrmation, and future studies are needed
to determine their underlying biological mechanisms.
In a previous publication, Parkin et al. [7] found that
the highest estimated rates of prostate cancer in Africa were
seen in the South followed by Central, West, East, and
North African regions. However, these 2008 estimates were
for regional populations of all races combined and thus are
not necessarily speciﬁc to blacks. For example, Parkin et al.
[7] noted that the high rate of 40.5 per 100,000 man-years
reported for Southern Africa was the composite of the rates
among various racial groups. In South Africa alone, the rates
ranged from a high of 41.1 per 100,000 man-years among
whites, to 25.4 among mixed races, 14.3 among blacks, and
13.0 among Indians [3]. Because race is a well-established
riskfactorforprostatecancer,amorecomparableassessment
ofprostatecancerratesinAfricaforcomparisonwithAfrican
Americans necessitates comparison of black-speciﬁc rates, as
in the current study.
4. Conclusions
Although data are limited, our analysis showed that (1)
reported total prostate cancer incidence in Africa is lower
than that among African Americans; (2) rates vary substan-
tially (8-fold) within Sub-Saharan Africa, with rates lowest
in the West and highest in the East; (3) total prostate
cancer rates in Africa are similar to distant-stage disease
rates in the US; (4) incidence appears to be rising in several
African countries. It should be noted that when making
inferencesfromtheseﬁndings,considerationshouldbegiven
to limitations in data quality. Undoubtedly, with improved
economies and clinical diagnosis as well as increased West-
ernization, incidence rates in Africa are likely to continue to
rise. Therefore, a high priority in this population should be
the implementation ofhigh-quality population-based cancer
registration to monitor incidence rates in Africa and to
develop eﬀective cancer prevention strategies.
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